Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use

INTRODUCTION: There are currently no approved treatments solely for unclassifiable interstitial lung disease (uILD); however, a recent trial showed this population can benefit from pirfenidone. We report a subgroup analysis of this trial to assess the effects of immunomodulators (concomitant mycophe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreuter, Michael, Maher, Toby M., Corte, Tamera J., Molina-Molina, Maria, Axmann, Judit, Gilberg, Frank, Kirchgaessler, Klaus-Uwe, Cottin, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866297/
https://www.ncbi.nlm.nih.gov/pubmed/34936057
http://dx.doi.org/10.1007/s12325-021-02009-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866297/
https://www.ncbi.nlm.nih.gov/pubmed/34936057
http://dx.doi.org/10.1007/s12325-021-02009-w

Ejemplares similares